NSC745885
|
|
|
- CAS号:
- 4219-52-7
- 英文名:
- NSC745885
- 英文别名:
- NSC745885;NSC-745885,NSC745885;Anthra[1,2-c][1,2,5]thiadiazole-6,11-dione
- 中文名:
- NSC745885
- 中文别名:
- 化合物 T16354
- CBNumber:
- CB58054639
- 分子式:
- C14H6N2O2S
- 分子量:
- 266.27
- MOL File:
- 4219-52-7.mol
|
|
|
NSC745885化学性质
-
沸点:
-
470.0±14.0 °C(Predicted)
-
|
-
密度:
-
1.574±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: < 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension.
-
|
-
酸度系数(pKa):
-
-1.90±0.20(Predicted)
-
|
NSC745885性质、用途与生产工艺
NSC745885 是一种有效的抗肿瘤 (anti-tumor) 试剂，对多种癌细胞株有选择性毒性，但对正常细胞没有毒性。NSC745885 是一种有效的 EZH2 的下调因子通过蛋白酶体降解途径。NSC745885 为晚期膀胱癌和口腔鳞癌的研究提供了可能性。
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the
densities of cultured cells when compared with untreated cells. The IC
50
of NSC745885 is 0.85 μM after 72 hours’ treatment.NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.
Cell Viability Assay
|
Cell Line:
|
SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
|
|
Concentration:
|
0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM
|
|
Incubation Time:
|
24, 48, or 72 hours
|
|
Result:
|
Decreases SAS cells growth as a time and dose-dependent manner.
|
Apoptosis Analysis
|
Cell Line:
|
SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
|
|
Concentration:
|
0.5 μM, 1 μM, 1.5 μM, 2 μM, 4 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
Decreases SAS cells growth as a time and dose-dependent manner.
|
Western Blot Analysis
|
Cell Line:
|
SAS cells is obtained from a poorly differentiated human squamous cell carcinoma
|
|
Concentration:
|
0.5 μM, 1 μM, 1.5 μM, 2 μM
|
|
Incubation Time:
|
24 or 48 hours
|
|
Result:
|
Increased cleaved caspase-3 expression and decreased XIAP expression.
|
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.
|
Animal Model:
|
Eight-week-old NOD/SCID (NOD.CB17
Prkdc
scid
/J) mice
|
|
Dosage:
|
2 mg/kg
|
|
Administration:
|
Intraperitoneal injection; 2 mg/kg; once daily; 10 days
|
|
Result:
|
Inhibited engrafted tumors growth in vivo.
|
NSC745885
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-119198 | NSC745885
NSC745885 | 4219-52-7 | 5mg | 2000元 |
| 2024/04/30 | HY-119198 | NSC745885
NSC745885 | 4219-52-7 | 10mg | 3200元 |
4219-52-7, NSC745885 相关搜索:
- 化合物 T16354
- 4219-52-7
- Anthra[1,2-c][1,2,5]thiadiazole-6,11-dione
- NSC-745885,NSC745885
- NSC745885